These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1079053)

  • 21. Evidence for a centrally mediated hypotensive effect of L-dopa in the rat.
    Henning M; Rubenson A
    J Pharm Pharmacol; 1970 Mar; 22(3):241-3. PubMed ID: 4399501
    [No Abstract]   [Full Text] [Related]  

  • 22. Mechanism of action of methyldopa in the rat. Role of 3-O-methylated metabolites.
    Zavisca FG; Breau AP; Wurtman RJ
    Circ Res; 1979 Nov; 45(5):684-90. PubMed ID: 487531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
    Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Crotty K; Mueller RA
    J Pharmacol Exp Ther; 1984 Nov; 231(2):343-54. PubMed ID: 6149306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of aromatic amino acid decarboxylase and depletion of biogenic amines in brain of rats treated with alpha-monofluoromethyl p-tyrosine: similitudes and differences with the effects of alpha-monofluoromethyldopa.
    Jung MJ; Hornsperger JM; Gerhart F; Wagner J
    Biochem Pharmacol; 1984 Jan; 33(2):327-30. PubMed ID: 6704155
    [No Abstract]   [Full Text] [Related]  

  • 25. Depression of sympathetic nervous function by DL-alpha-monofluoromethyldopa, an enzyme-activated, irreversible inhibitor of L-aromatic amino acid decarboxylase.
    Fozard JR; Spedding M; Palfreyman MG; Wagner J; Möhring J; Koch-Weser J
    J Cardiovasc Pharmacol; 1980; 2(3):229-45. PubMed ID: 6156322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Participation of dopamine- and serotonin- receptors in the disaggregation of brain polysomes by L-dopa and L-5-HTP.
    Weiss BF; Liebschutz JL; Wurtman RJ; Munro HN
    J Neurochem; 1975 Jun; 24(6):1191-5. PubMed ID: 1079238
    [No Abstract]   [Full Text] [Related]  

  • 27. L-3,4-dihydroxyphenylalanine-induced of norepinephrine from the rat heart.
    Landsberg L
    Biochem Pharmacol; 1971 Dec; 20(12):3542-7. PubMed ID: 5132898
    [No Abstract]   [Full Text] [Related]  

  • 28. Potentiation of the central nervous system effects of DOPA by decarboxylase inhibition: possible direct role of this neuroamino acid in brain mechanisms.
    Vazquez AJ; Sabelli HC
    Exp Neurol; 1975 Jan; 46(1):44-56. PubMed ID: 1109342
    [No Abstract]   [Full Text] [Related]  

  • 29. Thiol compounds. III Synthesis and antihypertensive activity of mercaptoacylamino acids.
    Oya M; Kato E; Matsumoto J; Kawashima Y; Iwao J
    Chem Pharm Bull (Tokyo); 1981 May; 29(5):1203-13. PubMed ID: 6794916
    [No Abstract]   [Full Text] [Related]  

  • 30. Cardiovascular effects of levodopa.
    Goldberg LI; Whitsett TL
    Clin Pharmacol Ther; 1971; 12(2):376-82. PubMed ID: 5577486
    [No Abstract]   [Full Text] [Related]  

  • 31. Saligenin analogs of l-DOPA and dl-alpha-methyl-DOPA.
    Atkinson M; Hartley D; Lunts LH; Ritchie AC
    J Med Chem; 1974 Feb; 17(2):248-9. PubMed ID: 4809259
    [No Abstract]   [Full Text] [Related]  

  • 32. Dopamine metabolism following irreversible inactivation of aromatic amino acid decarboxylase in retina.
    Parkinson D; Baughman R; Masland RH; Rando RR
    J Neurosci; 1981 Nov; 1(11):1205-10. PubMed ID: 6796656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes.
    Watanabe AM; Chase TN; Cardon PV
    Clin Pharmacol Ther; 1970; 11(5):740-6. PubMed ID: 5455636
    [No Abstract]   [Full Text] [Related]  

  • 34. Dopamine: mediator of brain polysome disaggregation after L-dopa.
    Weiss BF; Munro HN; Ordonez LA; Wurtman RJ
    Science; 1972 Aug; 177(4049):613-6. PubMed ID: 4403139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Central hypotensive effect of L-3,4-dihydroxyphenylalanine in the rat.
    Henning M; Rubenson A
    J Pharm Pharmacol; 1970 Aug; 22(8):553-60. PubMed ID: 4394527
    [No Abstract]   [Full Text] [Related]  

  • 36. Synthetic and preliminary hemodynamic and whole animal toxicity studies on (R,S)-, (R)-, and (S)-2-methyl-3-(2,4,5-trihydroxyphenyl)alanine.
    Musson DG; Karashima D; Rubiero H; Melmon KL; Cheng A; Castagnoli N
    J Med Chem; 1980 Dec; 23(12):1318-23. PubMed ID: 7452683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacological actions of 3,4-dihydroxyphenyl-alpha-methylalanine (alpha-methyldopa), an inhibitor of 5-hydroxytryptophan decarboxylase.
    SMITH SE
    Br J Pharmacol Chemother; 1960 Jun; 15(2):319-27. PubMed ID: 13832156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potentiation of effects of L-dopa on conditioned avoidance behavior by inhibition of extracerebral dopa decarboxylase.
    Seiden LS; Martin TW
    Physiol Behav; 1971 Apr; 6(4):453-8. PubMed ID: 5148757
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of methyldopa and related agents on pressor responses to tyramine in reserpine-pretreated rats and dogs.
    Torchiana ML; Wenger HC; Stavorski J; Ludden CT; Stone CA
    J Pharmacol Exp Ther; 1966 Feb; 151(2):242-52. PubMed ID: 5932601
    [No Abstract]   [Full Text] [Related]  

  • 40. The depression of sensitivity to noradrenaline caused by L-dopa.
    Eden E; Nasmyth PA
    J Physiol; 1973 Apr; 230(1):7P-8P. PubMed ID: 4702454
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.